Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk

Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Christine M., Mendes, Margaret A.S., Ma, Joseph D.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094768/
https://www.ncbi.nlm.nih.gov/pubmed/21593964
http://dx.doi.org/10.1371/currents.RRN1236
Descripción
Sumario:Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. Thiopurine drugs are metabolized, in part, by thiopurine methyltransferase (TPMT). TPMT displays genetic polymorphism resulting in null or decreased enzyme activity. At least 20 polymorphisms have been identified, of which, TPMT *2, *3A, *3B, *3C, and *4 are the most commonly studied. These polymorphisms have been associated with increased myelosuppression risk. TPMT genotyping may be useful to predict this risk.

Ejemplares similares